Traci DeVito, and Naveed Saleh, MD, MS
In this installment of Oncology Drug Updates, updates to FDA approvals for pembrolizumab in the treatment of lung cancer and RCC are highlighted.
FoundationOne®CDx analyzes all recommended genomic biomarkers for solid tumors and provides direct paths to therapy for companion diagnostic indications. This one test can help guide therapy selection and clinical trial options for more patients.
This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.
This email was sent by: MultiMedia Healthcare
535 Connecticut Avenue, Suite 300
Norwalk, CT, 06854, USA